Compare Fastenal Company Common Stock (FAST) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fastenal Company Common Stock vs Organon & Co. Common Stock — how do they compare? Fastenal Company Common Stock trades at $52.45 (market cap $59.02B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Fastenal Company Common Stock is far larger — about 16.3× Organon & Co. Common Stock's market cap, and Fastenal Company Common Stock pays the higher dividend (1.87%). Which is the better fit depends on your goals — on Pluang, investors hold Fastenal Company Common Stock for 2 Days and Organon & Co. Common Stock for 0 Days on average.
| FAST | OGN | |
|---|---|---|
Market Cap | $59.02B | $3.62B |
Volume | 10,054,911 | 2,892,999 |
Sector | Industrials | Health |
52-Week High | $52.38 | $13.81 |
52-Week Low | $39.15 | $5.70 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $59.25B | $11.04B |
Dividend Yield | 1.87% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fastenal (FAST) trades at $51.43, down 0.12% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with Q3 2026 earnings of $0.35 per share beating estimates, marking the fourth consecutive quarterly beat. Revenue grew 15.5% year-over-year to $2.46 billion, driven by market share gains and new contract wins. The stock shows resilience with consistent operational performance despite premium valuation metrics.
Outlook remains positive with strong industrial demand and digital initiatives supporting growth, though the elevated P/E ratio of 43.96 presents valuation risk. Analyst consensus leans cautious with 59% hold ratings, suggesting limited near-term upside from current levels. Key risks include economic sensitivity and competitive pressures in industrial distribution.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fastenal Company Common Stock
Fastenal distributes fasteners, tools, safety supplies, and other industrial products. It also provides inventory management and vending solutions for business customers.
Read more on FAST →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
